“One way or other, we don’t think ATL-1102 can remain the centerpiece of the story put forward to investors,” Garner told investors in a webinar this morning.
In summary, the trial failed to detect any meaningful difference between the boys actively treated with ATL-1102, compared with the placebo cohort. [Read More: Percheron Disappointed in Avicursen (ATL1102) Study For Duchenne (DMD)]
Read More: Clinical Trials for Duchenne (List of All Researches)
- Follow Us -
